Academic interests
- Clinical costing – Cost per patient
- Merging and restructuring hospitals
- Internal resource management
Courses taught
Background
- OR Nurse
- Master in Health adm
- DrPhil
Positions held
- Senior advisor CEO Office at The Oslo University Hospital
Publications
-
-
Schive, Simen Walberg; Foss, Aksel; Sahraoui, Afaf; Kloster-Jensen, Kristine; Hafsahl, Geir & Kvalheim, Gunnar
[Show all 15 contributors for this article]
(2017).
Cost and clinical outcome of islet transplantation in Norway 2010-2015.
Clinical Transplantation.
ISSN 0902-0063.
31:e12871(1),
p. 1–8.
doi:
10.1111/ctr.12871.
Show summary
Islet transplantation is a minimally invasive β-cell replacement strategy. Islet transplantation is a reimbursed treatment in Norway. Here, we summarize the cost and clinical outcome of 31 islet transplantations performed at Oslo University Hospital (OUS) from January 2010 to June 2015. Patients were retrospectively divided into three groups. Thirteen patients received either one or two islet transplantation alone (ITA), while five patients received islet transplantation after previous solid organ transplantation. For the group receiving 2 ITA, Kaplan-Meier estimates show an insulin independence of 20% more than 4 years after their last transplantation. An estimated 70% maintain at least partial graft function, defined as fasting C-peptide >0.1 nmol L−1, and 47% maintain a HbA1c below 6.5% or 2 percent points lower than before ITA. For all groups combined, we estimate that 44% of the patients have a 50% reduction in insulin requirement 4 years after the initial islet transplantation. The average cost for an islet transplantation procedure was 347 297±60 588 NOK, or 35 424±6182 EUR, of which isolation expenses represent 34%. We hereby add to the common pool of growing experience with islet transplantation and also describe the cost of the treatment at our center.
-
Mishra, Vinod Kumar; Fiane, Arnt E; Winsnes, Benny Adam; Geiran, Odd; Sørensen, Gro & Hagen, Terje P.
[Show all 7 contributors for this article]
(2017).
Cardiac Replacement Therapies: Outcomes and Costs for Heart Transplantation versus Circulatory Assist.
Scandinavian Cardiovascular Journal.
ISSN 1401-7431.
51(1),
p. 1–7.
doi:
10.1080/14017431.2016.1196826.
-
-
Mishra, Vinod Kumar; Fiane, Arnt E; Geiran, Odd; Sørensen, Gro; Khushi, Ishtiaq & Hagen, Terje P.
(2012).
Hospital costs fell as numbers of LVADs were increasing: experiences from Oslo University Hospital.
Journal of Cardiothoracic Surgery.
ISSN 1749-8090.
Aug(27).
doi:
10.1186/1749-8090-7-76.
-
Mishra, Vinod Kumar; Geiran, Odd; Fiane, Arnt E; Sørensen, Gro; Andresen, Sølvi & Olsen, Ellen Kristin
[Show all 8 contributors for this article]
(2010).
Costs and reimbursement gaps following implementation of 3rd generation Left Ventricular Assist Devices.
The Journal of Heart and Lung Transplantation.
ISSN 1053-2498.
29(1),
p. 72–78.
doi:
10.1016/j.healun.2009.06.029.
Show summary
BACKGROUND: The purpose of this study was to compare and contrast total hospital costs and subsequent reimbursement of implementing a new program using a third-generation left ventricular assist device (LVAD) in Norway.
METHODS: Between July 2005 and March 2008, the total costs of treatment for 9 patients were examined. Costs were calculated for three periods—the pre-implantation LVAD phase, the LVAD implantation phase and the post-implantation LVAD phase—as well as for total hospital care. Patientspecific costs were obtained prospectively from patient records and included personnel resources,
medication, blood products, blood chemistry and microbiology, imaging, and procedure costs including
operating room costs. Overhead costs were registered retrospectively and allocated to the specific
patient by pre-defined allocation keys. Finally, patient-specific costs and overhead costs were aggregated
into total patient costs.
RESULTS: The average total patient cost in 2007 U.S. dollars was $735,342 and the median was $613,087 (range $342,581 to $1,256,026). The mean length of stay was 77 days (range 40 to 127 days). For the LVAD implantation phase, the mean cost was $457,795 and median cost was $458,611 (range
$246,239 to $677,680). The mean length of stay for the LVAD implantation phase was 55 days (range 25 to 125 days). The diagnosis-related group (DRG) reimbursement (2007) was $143,192.
CONCLUSIONS: There is significant discrepancy between actual hospital costs and the current Norwegian DRG reimbursement for the LVAD procedure. This discrepancy can be partly explained by excessive costs related to the introduction of a new program with new technology. Costly innovations
should be considered in price setting of reimbursement for novel technology.
-
-
Mishra, Vinod Kumar; Geiran, Odd; Krohg-Sørensen, Kirsten & Andresen, S
(2008).
Thoracic aortic aneurysm repair. Direct hospital cost and Diagnosis Related Group reimbursement.
Scandinavian Cardiovascular Journal.
ISSN 1401-7431.
42,
p. 77–84.
doi:
10.1080/14017430701716814.
View all works in Cristin
-
Bjørnelv, Gudrun Maria Waaler; Fretland, Åsmund Avdem; Edwin, Bjørn; Kristiansen, Ronny; Engvik, Linda & Mishra, Vinod Kumar
[Show all 8 contributors for this article]
(2016).
COST-EFFECTIVENESS OF REPLACING OPEN LIVER RESECTION WITH LAPAROSCOPIC LIVER RESECTION FOR PATIENTS WITH COLORECTAL LIVER METASTASES. ANALYSES PERFORMED ALONGSIDE A RANDOMIZED CONTROLLED TRIAL: THE OSLO-COMET STUDY.
-
Mishra, Vinod Kumar; Brinch, Lorentz; Ernst, Peter; Lønset, May Kristin; Tangen, Jon Magnus & Wikelund, Jenny
[Show all 13 contributors for this article]
(2009).
Kostnadsstudie av høydosebehandling med autolog stamcellestøtte ved fire norske sentra.
Helseøkonomisk forskningsprogram ved Universitetet i Oslo.
ISSN 978-82-7756-201-8.
2009(1).
View all works in Cristin
Published
Apr. 13, 2011 2:45 PM
- Last modified
Apr. 15, 2014 12:22 PM